Adjuvant statin therapy for oesophageal adenocarcinoma: the STAT‐ROC feasibility study

Alexandre, L., Clark, A. B. ORCID:, Walton, S., Lewis, M. P., Kumar, B., Cheong, E. C., Warren, H., Kadirkamanathan, S. S., Parsons, S. L., Dresner, S. M., Sims, E., Jones, M., Hammond, M., Flather, M., Loke, Y. K., Swart, A. M. ORCID: and Hart, A. R. (2020) Adjuvant statin therapy for oesophageal adenocarcinoma: the STAT‐ROC feasibility study. BJS Open, 4 (1). pp. 59-70. ISSN 2474-9842

[thumbnail of Published_Version]
PDF (Published_Version) - Published Version
Available under License Creative Commons Attribution.

Download (318kB) | Preview


Background Statins inhibit proliferative signalling in oesophageal adenocarcinoma (OAC) and their use is associated with better survival in observational studies. The present study was undertaken to examine the feasibility of assessing adjuvant statin therapy in patients with operable OAC in a phase III RCT. Methods For this multicentre, double‐blind, parallel‐group, randomized, placebo‐controlled feasibility trial, adults with OAC (including Siewert I–II lesions) who had undergone oesophagectomy were centrally allocated (1 : 1) to simvastatin 40 mg or matching placebo by block randomization, stratified by centre. Participants, clinicians and investigators were blinded to treatment allocation. Patients received treatment for up to 1 year. Feasibility outcomes were recruitment, retention, drug absorption, adherence, safety, quality of life, generalizability and survival. Results A total of 120 patients were assessed for eligibility at four centres, of whom 32 (26·7 per cent) were randomized, 16 in each group. Seven patients withdrew. Participants allocated to simvastatin had lower low‐density lipoprotein cholesterol levels by 3 months (adjusted mean difference −0·83 (95 per cent c.i. −1·4 to −0·22) mmol/l; P = 0·009). Median adherence to medication was greater than 90 per cent between 3 and 12 months' follow‐up. Adverse events were similar between the groups. Quality‐of‐life data were complete for 98·3 per cent of questionnaire items. Cardiovascular disease, diabetes and aspirin use were more prevalent in the non‐randomized group, whereas tumour site, stage and grade were similar between groups. Survival estimates were imprecise. Conclusion This RCT supports the conduct and informs the design considerations for a future phase III trial of adjuvant statin therapy in patients with OAC. Registration number: ISRCTN98060456 (www.isrctn/com).

Item Type: Article
Additional Information: © 2019 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.
Uncontrolled Keywords: cancer,chemotherapy,double-blind,ldl cholesterol,open-label,plus simvastatin,previously treated patients,randomized phase-ii,survival,trial,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 17 Dec 2019 03:31
Last Modified: 20 Dec 2022 22:33
DOI: 10.1002/bjs5.50239

Actions (login required)

View Item View Item